AACE Clinical Case Reports (Nov 2019)

Central Precocious Puberty in two Boys with Prader-Willi Syndrome on Growth Hormone Treatment

  • Elena Monai, MD,
  • Anders Johansen, MD, PhD,
  • Erik Clasen-Linde, MD,
  • Ewa Rajpert-De Meyts, MD, DMSc,
  • Niels Erik Skakkebæk, MD, DMSc,
  • Katharina M. Main, MD, PhD,
  • Anne Jørgensen, MSc, PhD,
  • Rikke Beck Jensen, MD, PhD

Journal volume & issue
Vol. 5, no. 6
pp. e352 – e356

Abstract

Read online

ABSTRACT: Objective: Prader-Willi syndrome (PWS) is a rare genetic neuroendocrine disorder characterized by hypotonia, obesity, short stature, and mental retardation. Incomplete or delayed pubertal development as well as premature adrenarche are usually found in PWS, whereas central precocious puberty is rarely seen. Methods: This study reports the clinical, biochemical, and histologic findings in 2 boys with PWS who developed central precocious puberty. Results: Both boys were started on growth hormone therapy during the first years of life according to the PWS indication. They had both bilateral cryptorchidism at birth and had orchidopexy in early childhood. Retrospective histologic analysis of testicular biopsies demonstrated largely normal tissue architecture and germ cell maturation, but severely decreased number of prespermatogonia in one of the patients. Both boys had premature adrenarche around the age of 6. Precocious puberty was diagnosed in both boys with enlargement of testicular volume (>3 mL), signs of virilization and a pubertal response to a gonadotropin-releasing hormone (GnRH) test and they were both treated with GnRH analog. Conclusion: The cases described here displayed typical characteristics for PWS, a considerable heterogeneity of the hypothalamic-pituitary function, as well as testicular histology. Central precocious puberty is extremely rare in PWS boys, but growth hormone treatment may play a role in the pubertal timing.